Celldex cancer vax could be fast-tracked; Prof who falsified HIV vaccine data gets prison sentence;

> Celldex's ($CLDX) cancer vaccine, Rintega, could be fast-tracked. Joseph Pantginis and Assaf Vestin of Roth Capital Partners predicted it will be the second cancer vaccine approved in the U.S. More

> Dong Pyou Han, who falsified HIV vaccine research, was sentenced to more than four and a half years in prison and ordered to repay $7.2 million in grants his team received from the federal government. Story

> India's Hilleman Labs announced it has made a breakthrough in its quest for an affordable Haemophilus influenzae type B (Hib) vaccine. Report

> The Indian government has called on the private sector to help develop cost-effective vaccines to boost its immunization program. Article

> Siemens and BioNTech are collaborating to produce personalized cancer vaccines on a commercial scale. News

Suggested Articles

The U.K.'s two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses while expanding clinical trials.

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.